A 10-year, single-institution analysis of clinicopathologic features and sentinel lymph node biopsy in thin melanomas - 23/10/13
Abstract |
Background |
The 2009 American Joint Committee on Cancer criteria for thin cutaneous melanomas recommend staging sentinel lymph node (SLN) biopsy (SLNB) for select stage IB tumors. SLNB in this population remains controversial because of low rates of node positivity and inconsistent prognostic parameters.
Objective |
The purpose of this study was to examine the association between multiple clinicopathologic features and SLNB result, and clinical outcome.
Methods |
Clinical and pathologic parameters from patients with melanomas less than or equal to 1.00 mm receiving wide local excision with SLNB at our institution from 2001 through 2010 were recorded. Analysis for any statistically significant relationships between recorded parameters and SLN results and outcome were performed.
Results |
A total of 189 cases yielded 3 positive SLNBs (1.6%). Disease progression occurred in 6 cases (3.2%). Positive SLNB predicted distant metastasis and death from disease (P = .0017). Mitotic rate was not associated with a positive SLNB result.
Limitations |
The follow-up time for this study was limited (mean = 40.7 months).
Conclusion |
Our data confirm a statistically significant relationship between SLNB result and likelihood for distant metastasis in thin melanoma. There was a trend for a relationship between mitotic rate and clinical outcome. This relationship reached statistical significance at a mitotic rate of greater than 3 mitoses/mm2.
Le texte complet de cet article est disponible en PDF.Key words : American Joint Committee on Cancer, melanoma prognosis, mitotic rate, sentinel lymph node biopsy, thin melanoma, ulceration
Abbreviations used : AJCC, SLN, SLNB
Plan
| Funding sources: None. |
|
| Disclosure: Dr Gerami has served as a consultant to Abbott Molecular Labs, Dermtech International, Castle Biosciences, Myriad Genomics, and Neogenomics and has received honoraria for this. Dr Rademaker has served on the advisory board of Georgetown University Cancer Center and as a consultant for the National Institutes of Health and has received honoraria for this. Dr Martini has served on the advisory board of Dove/Unilever and has received honoraria for this. Ms Cooper and Drs Wayne, Damstetter, Gordon, Guitart, West, and Nardone have no conflicts of interest to declare. |
Vol 69 - N° 5
P. 693-699 - novembre 2013 Retour au numéro
Article précédent
- Margin comments in dermatopathology reports on dysplastic nevi influence re-excision rates
- Nneka I. Comfere, Rima Chakraborty, Margot S. Peters
- Amelanotic acral melanomas: Clinicopathological, BRAF mutation, and KIT aberration analyses
- Yoo Duk Choi, Seung Min Chun, Sun A. Jin, Jee-Bum Lee, Sook Jung Yun
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?